Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study

International Journal of Cardiology

Volumn 147, Issue 2, 2011, Pages 314-315

  Pasqui, Anna Laura ^a   Maffei, Silvia ^b   Di Renzo, Michela ^a   Pompella, Gerarda ^a   Auteri, Alberto ^a   Puccetti, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Heart failure; IL10; IL6; Levosimendan; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; LEVOSIMENDAN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 79951944544     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.065     Document Type: Article

References (15)

1. McBride B, White M. Levosimendan: implications for clinicians. J Clin Pharmacol 2003;43:1071-81. (Pubitemid 37174438)
2. Parissis J, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-12. (Pubitemid 38595693)
3. Trikas A, Antoniades C, Latsios G, et al. Long-term effect of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006;8:804-9. (Pubitemid 44779417)
4. Aukrust P, Ueland T, Lien E. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82. (Pubitemid 29066497)
5. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44. (Pubitemid 30167009)
6. Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 2001;3:415-21. (Pubitemid 32776868)
7. Pasqui AL, Di Renzo M, Maffei S, et al. Pro/anti-inflammatory cytokine imbalance in post-ischemic left ventricular remodeling. Mediat Inflamm 2010, doi:10.1155/2010/974694.
8. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin10 in atherosclerosis. Circ Res 1999:e17-24.
9. Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Society of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
10. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.
11. Pasqui AL, Di Renzo M, Auteri A, Puccetti L. Cytokines in acute coronary syndromes. Int J Cardiol 2005;105:355-6. (Pubitemid 41605096)
12. Adamopoulos S, Parissis J, Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517-26. (Pubitemid 34619192)
13. Hasenfusse G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7. (Pubitemid 28527473)
14. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7.
15. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.